Nasdaq warns InterCure (Nasdaq: INCR) on sub-$1 share price and listing

Rhea-AI Filing Summary

InterCure Ltd. reported that it received a Nasdaq notice on February 25, 2026 stating that its ordinary shares failed to meet the minimum bid requirement, having closed below $1.00 for 30 consecutive business days. Under Nasdaq rules, InterCure has until August 24, 2026 to regain compliance by maintaining a closing bid price at or above $1.00 for at least 10 consecutive business days.

The company expects it could qualify for an additional 180‑day grace period if it meets other Nasdaq Capital Market standards and applies to transfer. InterCure is monitoring its share price and is considering a reverse share split, subject to corporate and regulatory approvals, as part of its plan. Its shares will continue trading on the Nasdaq Global Market while it works to restore compliance.

Positive

• None.

Negative

• Nasdaq minimum bid deficiency and delisting risk: InterCure received a Nasdaq notice that its ordinary shares traded below $1.00 for 30 consecutive business days, triggering a 180‑day compliance period and the possibility of delisting if compliance is not regained.

Insights

Equity Markets & Listing Standards Analyst

Nasdaq bid-price deficiency introduces listing risk for InterCure.

InterCure has fallen out of compliance with Nasdaq’s $1.00 minimum bid rule after 30 consecutive business days below that level. Nasdaq granted a 180‑day window, until August 24, 2026, during which the company must achieve at least 10 consecutive trading days at or above that threshold.

If it fails, InterCure expects to seek an additional 180‑day period by transferring to the Nasdaq Capital Market and meeting all initial listing standards other than bid price. The company states it is considering a reverse share split, pending approvals, alongside business initiatives as tools to restore compliance.

During the grace period, the shares remain on the Nasdaq Global Market, but the filing notes that continued non‑compliance could ultimately lead to delisting. Future company disclosures will clarify whether conditions for an extension are met and whether any corporate actions, such as a reverse split, are implemented.

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Form 6-K

Report of Foreign Private Issuer

Pursuant to Rule 13a-16 or 15d-16

of the Securities Exchange Act of 1934

For the month of March 2026

Commission File Number: 001-40614

INTERCURE LTD.

(Translation of registrant’s name into English)

85 Medinat ha-Yehudim Street

Herzliya, 4676670, Israel

Tel: +972 77 460 5012

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.

Form 20-F ☒ Form 40-F ☐

On March 3, 2026, InterCure Ltd. (the “Registrant”) issued a press release titled “InterCure Receives Nasdaq Notification Regarding Minimum Bid Requirement,” a copy of which is furnished as Exhibit 99.1 with this report of Foreign Private Issuer on Form 6-K.

Exhibit No.
99.1		Press Release issued by InterCure Ltd. on March 3, 2026, titled “InterCure Receives Nasdaq Notification Regarding Minimum Bid Requirement.”

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	INTERCURE LTD.
Date: March 3, 2026	/s/ Amos Cohen
	Amos Cohen
	Chief Financial Officer

Exhibit 99.1

InterCure Receives Nasdaq Notification Regarding Minimum Bid Requirement

NEW YORK and HERZLIYA, Israel, March 3, 2026 - InterCure Ltd. (Nasdaq: INCR) (TASE: INCR) (“InterCure” or the “Company”) today announced that on February 25, 2026 the Company received a written notice (the “Notice”) from the Nasdaq Stock Market LLC indicating that the Company was not in compliance with Nasdaq Listing Rule 5450(a)(2), as the Company’s closing bid price for its ordinary shares, or Ordinary Shares, was below $1.00 per share for the last 30 consecutive business days.

Pursuant to Nasdaq Listing Rule 5810(c)(3)(A), the Company has been granted a 180-calendar day compliance period, or until August 24, 2026, to regain compliance with the minimum bid price requirement. To regain compliance, the closing bid price of the Ordinary Shares must meet or exceed $1.00 per share for at least 10 consecutive business days during the 180-calendar day compliance period.

If the Company is not in compliance by August 24, 2026, the Company expects to be eligible for an additional 180-calendar day compliance period. To qualify for this additional time, the Company will be required to submit a transfer application and meet the continued listing requirement for market value of publicly held shares and all other initial listing standards for the Nasdaq Capital Market, with the exception of the minimum bid price requirement, and to provide written notice of its intention to cure the deficiency during such period.

The Company currently intends monitor the closing price of its Ordinary Shares and to consider effecting a reverse share split, subject to obtaining all required corporate and regulatory approvals, as part of its plan to regain compliance with the minimum bid price requirement, and believes that this measure, together with its ongoing business and strategic initiatives, will support the restoration of compliance within the applicable timeframe. The Company’s Ordinary Shares will continue to be listed and trade on the Nasdaq Global Market during this period, and are unaffected by the receipt of the written notice from Nasdaq.

If the Company does not regain compliance within the allotted compliance period(s), including any extensions that may be granted by Nasdaq, Nasdaq will provide notice that the Company’s Ordinary Shares will be subject to delisting.

This announcement is made in compliance with Nasdaq Listing Rule 5810(b), which requires prompt disclosure of receipt of a deficiency notification.

About InterCure (dba Canndoc)

InterCure (dba Canndoc) (Nasdaq: INCR) (TASE: INCR) is the leading, profitable, and one of the fastest growing cannabis companies outside of North America. Canndoc, a wholly owned subsidiary of InterCure, is Israel’s largest licensed cannabis producer and one of the first to offer Good Manufacturing Practices (GMP) certified and pharmaceutical-grade medical cannabis products. InterCure leverages its market leading distribution network, best in class international partnerships and a high-margin vertically integrated “seed-to-sale” model to lead the fastest growing cannabis global market outside of North America.

For more information, visit: https://www.intercure.co

Forward-Looking Statements

This press release contains forward-looking statements pursuant to U.S. federal securities laws. Forward-looking statements may include, but are not limited to, statements regarding the Company’s ability to regain compliance with Nasdaq’s minimum bid price requirement, the timing and potential effectiveness of any actions the Company may undertake to cure such deficiency, including the implementation of a reverse share split, and other statements that are not historical facts. These forward-looking statements are often characterized by terminology such as “believes,” “hopes,” “may,” “anticipates,” “should,” “intends,” “plans,” “will,” “expects,” “estimates,” “projects,” “positioned,” “strategy” and similar expressions, and are based on current expectations, assumptions and assessments of the Company’s management in light of its experience and perception of historical trends, current conditions and expected future developments. Forward-looking statements are not guarantees of future performance and are subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied in such statements. These risks and uncertainties include, among others, the Company’s ability to meet Nasdaq’s continued listing requirements, obtain required approvals for any corporate actions, including a reverse share split, market conditions, and other factors beyond the Company’s control. More detailed information about the risks and uncertainties affecting the Company is contained under the heading “Risk Factors” in the Company’s most recent Annual Report on Form 20-F and in other filings that the Company has made and may make with the U.S. Securities and Exchange Commission. Except as required by law, the Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Company Contact:

InterCure Ltd.

Amos Cohen, Chief Financial Officer

amos@intercure.co

FAQ

What Nasdaq notification did InterCure (INCR) receive about its share price?

InterCure received written notice from Nasdaq that it no longer meets the $1.00 minimum bid requirement because its ordinary shares closed below that level for 30 consecutive business days, triggering a formal compliance period under Nasdaq rules.

How long does InterCure (INCR) have to regain Nasdaq minimum bid compliance?

InterCure has a 180‑calendar day period, until August 24, 2026, to regain compliance. It must achieve a closing bid price of at least $1.00 per share for a minimum of 10 consecutive business days within this timeframe.

Can InterCure (INCR) get more time beyond August 24, 2026 to meet Nasdaq rules?

If InterCure is still non‑compliant by August 24, 2026, it expects to be eligible for an additional 180‑day compliance period, subject to applying to transfer to the Nasdaq Capital Market and meeting all initial listing standards except the minimum bid price.

What actions is InterCure (INCR) considering to restore Nasdaq bid-price compliance?

InterCure states it intends to monitor its ordinary share price and is considering a reverse share split, subject to required corporate and regulatory approvals, as part of its broader plan and strategic initiatives aimed at regaining compliance with Nasdaq’s minimum bid requirement.

Will InterCure (INCR) shares continue trading on Nasdaq after the deficiency notice?

Yes. The company states that its ordinary shares will continue to be listed and trade on the Nasdaq Global Market during the compliance period. Trading is not immediately affected by the notice, though persistent non‑compliance could eventually result in delisting.

What happens if InterCure (INCR) ultimately fails to regain Nasdaq compliance?

If InterCure does not regain compliance within the initial and any extended compliance periods, Nasdaq will issue a notice that its ordinary shares are subject to delisting. At that point, the company could pursue available appeal or alternative listing options under Nasdaq procedures.

Filing Exhibits & Attachments

2 documents

Press Releases

• EX-99.1 EX-99.1 13.2 KB
• EX-99 GRAPHIC 4.2 KB